New hope for hard-to-treat bile duct cancer: drug duo targets KRAS mutation
Disease control
Recruiting now
This study tests a new combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change called a KRAS mutation. The cancer must have worsened after at least one round of standard chemotherapy. The goal is to see if the c…
Phase: PHASE1, PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC